Lung cancer screening in Finland: a prospective randomized trial
DOI:
https://doi.org/10.2340/1651-226X.2025.43093Keywords:
Lung Cancer, cancer screening, LDCT, Smoking cessationAbstract
Background: Early detection of lung cancer with low-dose computed tomography (LDCT) screening can shift diagnoses to early-stage disease and improve survival. However, LDCT has several challenges such as high false positive rate and indefinite cost-effectiveness. We report here secondary and exploratory endpoints of the Low-dose CT screening for lung cancer combined with different smoking cessation approach in Finland (LDCT-SC-FI) study including recruitment channels, LDCT performance, and long-term smoking cessation.
Methods: In this study, we randomized 200 current smokers with a significant smoking history in 1:1 fashion to receive a smartphone application or standard of care written materials, both for smoking cessation. All underwent LDCT screening at baseline and at 1-year. Participants were recruited through multiple channels, including newspapers, internet advertisements, and healthcare referrals.
Results: Newspaper advertisements were the most effective recruitment method, accounting for 74.5% of participants while minority came through referrals (2.5%). LDCT screening demonstrated uptake of 96.7% for both rounds combined. Six lung cancers were detected with a positive predictive value of 75%. Of the detected lung cancers, five were at stage I and all of these underwent curative intent treatment. Smoking cessation rates at 1-year were higher in the application (18.3%) than in the control arm (12.8%), though the difference was not statistically significant (odds ratio [OR]: 1.53, 95% confidence interval [CI]: 0.69–3.41).
Interpretation: This study suggests that LDCT screening for lung cancer is feasible in Finland. The screening examination uptake was high with both screening rounds, while the positive predictive value for lung cancer detection remained at good level.
Downloads
References
Tesfaw LM, Dessie ZG, Mekonnen Fenta H. Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings. Front Oncol. 2023;13: 1308897.
https://doi.org/10.3389/FONC.2023.1308897 DOI: https://doi.org/10.3389/fonc.2023.1308897
de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382:503–13.
https://doi.org/10.1056/NEJMoa1911793 DOI: https://doi.org/10.1056/NEJMoa1911793
The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
https://doi.org/10.1056/NEJMoa1102873 DOI: https://doi.org/10.1056/NEJMoa1102873
Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for lung cancer: US preventive services task force recommendation statement. JAMA. 2021;325:962–70.
https://doi.org/10.1001/JAMA.2021.1117 DOI: https://doi.org/10.1001/jama.2021.1117
Van Der Aalst CM, Ten Haaf K, de Koning HJ. Implementation of lung cancer screening: what are the main issues? Transl Lung Cancer Res. 2021;10:1050.
https://doi.org/10.21037/TLCR-20-985 DOI: https://doi.org/10.21037/tlcr-20-985
Sedani AE, Davis OC, Clifton SC, Campbell JE, Chou AF. Facilitators and barriers to implementation of lung cancer screening: a framework-driven systematic review. J Natl Cancer Inst. 2022;114:1449–67.
https://doi.org/10.1093/JNCI/DJAC154 DOI: https://doi.org/10.1093/jnci/djac154
Wood DE, Kazerooni EA, Aberle D, Berman A, Brown LM, Eapen GA, et al. NCCN Guidelines® insights: lung cancer screening, Version 1.2022. J Natl Compr Canc Netw. 2022;20:754–64.
https://doi.org/10.6004/JNCCN.2022.0036 DOI: https://doi.org/10.6004/jnccn.2022.0036
Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, et al. ESR/ERS statement paper on lung cancer screening. Eur Respir J. 2020;55: 1900506.
https://doi.org/10.1183/13993003.00506-2019 DOI: https://doi.org/10.1183/13993003.00506-2019
Van Der Aalst CM, Van Klaveren RJ, Van Den Bergh KAM, Willemsen MC, De Koning HJ. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J. 2011;37:1466–73.
https://doi.org/10.1183/09031936.00035410 DOI: https://doi.org/10.1183/09031936.00035410
Brain K, Carter B, Lifford KJ, Burke O, Devaraj A, Baldwin DR, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Thorax. 2017;72:912–8.
https://doi.org/10.1136/THORAXJNL-2016-209690 DOI: https://doi.org/10.1136/thoraxjnl-2016-209690
Moldovanu D, de Koning HJ, van der Aalst CM. Lung cancer screening and smoking cessation efforts. Transl Lung Cancer Res. 2021;10.
https://doi.org/10.21037/TLCR-20-899 DOI: https://doi.org/10.21037/tlcr-20-899
Iivanainen S, Kurtti A, Wichmann V, Andersen H, Jekunen A, Kaarteenaho R, et al. Smartphone application versus written material for smoking reduction and cessation in individuals undergoing low-dose computed tomography (LDCT) screening for lung cancer: a phase II open-label randomised controlled trial. Lancet Reg Health Eur. 2024;42:100946.
https://doi.org/10.1016/J.LANEPE.2024.100946 DOI: https://doi.org/10.1016/j.lanepe.2024.100946
Xu DM, Gietema H, de Koning H, Vernhout R, Nackaerts K, Prokop M, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer. 2006;54:177–84.
https://doi.org/10.1016/j.lungcan.2006.08.006 DOI: https://doi.org/10.1016/j.lungcan.2006.08.006
Bevers TB, Niell BL, Baker JL, Bennett DL, Bonaccio E, Camp MS, et al. NCCN Guidelines® insights: breast cancer screening and diagnosis, Version 1.2023. J Natl Compr Canc Netw. 2023;21:900–9.
https://doi.org/10.6004/JNCCN.2023.0046 DOI: https://doi.org/10.6004/jnccn.2023.0046
Ness RM, Llor X, Abbass MA, Bishu S, Chen CT, Cooper G, et al. NCCN Guidelines® Insights: colorectal cancer screening, Version 1.2024. J Natl Compr Canc Netw. 2024;22:438–46.
https://doi.org/10.6004/JNCCN.2024.0047 DOI: https://doi.org/10.6004/jnccn.2024.0047
Djuric O, Venturelli F, Bassi MC, Gorini G, Paci E, Mantellini P, et al. Recruitment strategies and interventions to increase participation in lung cancer screening programmes: a systematic review protocol. BMJ Open. 2023;13:e074140.
https://doi.org/10.1136/BMJOPEN-2023-074140 DOI: https://doi.org/10.1136/bmjopen-2023-074140
Kallavus K, Laisaar KT, Rätsep A, Kiudma T, Takker U, Poola A, et al. National lung cancer screening program feasibility study in Estonia. Interdiscip Cardiovasc Thorac Surg. 2023;36: ivad041.
https://doi.org/10.1093/ICVTS/IVAD041 DOI: https://doi.org/10.1093/icvts/ivad041
Grover H, King W, Bhattarai N, Moloney E, Sharp L, Fuller L. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. Lung Cancer. 2022;170:20–33.
https://doi.org/10.1016/J.LUNGCAN.2022.05.005 DOI: https://doi.org/10.1016/j.lungcan.2022.05.005
Callister MEJ, Sasieni P, Robbins HA. Overdiagnosis in lung cancer screening. Lancet Respir Med. 2021;9:7–9.
https://doi.org/10.1016/S2213-2600(20)30553-1 DOI: https://doi.org/10.1016/S2213-2600(20)30553-1
Henderson LM, Su IH, Rivera MP, Pak J, Chen X, Reuland DS, et al. Prevalence of lung cancer screening in the US, 2022. JAMA Netw Open. 2024;7:e243190.
https://doi.org/10.1001/JAMANETWORKOPEN.2024.3190 DOI: https://doi.org/10.1001/jamanetworkopen.2024.3190
Yong PC, Sigel K, Rehmani S, Wisnivesky J, Kale MS. Lung cancer screening uptake in the United States. Chest. 2020;157:236.
https://doi.org/10.1016/J.CHEST.2019.08.2176 DOI: https://doi.org/10.1016/j.chest.2019.08.2176
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Viktor Wichmann, Sanna Iivanainen, Lauri Mattila, Veli-Pekka Kokkonen, Airi Jartti, Antti Kurtti, Riitta Kaarteenaho, Heidi Andersen, Antti Jekunen, Tuula Vasankari, Jussi Koivunen
This work is licensed under a Creative Commons Attribution 4.0 International License.
